Using Real-world Data to Support Product Label Change
A mid-size pharmaceutical
company was interested in
obtaining real-world evidence
demonstrating the safety and
effectiveness of higher dosage
chemotherapy for a labeled
oncology indication.
Assessing the Implications of Financial Requirements on Commercial Copay Assistance Program
A medium pharmaceutical company was launching a new oral drug in the diabetes space and wanted to understand how having specific income criteria for their commercial copay program would affect patient enrollment and the costs of program operation.
Linking EMR With SDOH Data: Insights Across Disease Cohorts Presentation
AMCP Spring 2024 Platinum Poster and Presentation.
Linking EMR With SDOH Data: Insights Across Disease Cohorts
AMCP Spring 2024 Platinum Poster.
Learnings from Linking Closed Claims Patient Cohorts with Consumer SDOH Data
ISPOR Spring 2024.
Using payer and age mix as the basis for developing a go-to-market strategy for a prelaunch drug
A biopharma company prepping to launch a biosimilar needed to know payer segments and patient age demographics.
Using published evidence and compendia to support expanded coverage for an off-label medication dosage
A pharma company needed to evaluate the likelihood that drug compendia would positively rate an off-label dosage of an FDA-approved medication to support additional payer coverage.
Pricing an oral formulation for a bioequivalent COPD product
A biopharma company needed an appropriate pricing model for a new tablet formulation of a successful existing infusion.